**Core tip:** The prevalence of hepatitis C virus (HCV) infection is high in patients with end-stage renal disease and HCV has clinical challenges in patients who undergo kidney transplantation. Historically, interferon-based treatment options have been limited by low rates of efficacy and significant side effects, including risk of precipitating rejection. Direct acting antiviral (DAA) drugs revolutionized the treatment of HCV. In this review we highlighted the most recent studies and clinical trial with DAA in renal patients including patients waiting for transplantation and already transplanted. In these studies all-oral DAA therapy appears to be safe and effective for such patients.

HEPATITIS C VIRUS EPIDEMIOLOGY
==============================

The World Health Organization (WHO) estimates that the global prevalence of hepatitis C virus (HCV) infection averages 3%, and the incidence is 3-4 millions of new infections every year\[[@B1]\]. HCV prevalence is not similar worldwide and ranges from less than 0.1% in Northern Europe to 1%-5% in other countries, such as Eastern Europe and the Indian subcontinent\[[@B2]\], to 25% in Egypt\[[@B2]\]. HCV infection is considered to be an endemic disease in some country as Taiwan\[[@B3]\].

HCV prevalence is increasing annually and the October 2017 report from the WHO revealed that 71 million of people are infected worldwide. However, some population-based studies\[[@B4]-[@B6]\] have demonstrated that prevalence estimates based on blood donors, underestimate the true HCV prevalence in the general population.

HCV AND RENAL DISEASE
=====================

HCV prevalence increases in patients with kidney diseases. HCV may cause chronic kidney disease (CKD) *via* some forms of glomerulonephritis (GN), primarily membranoproliferative GN (MPGN), which may be caused by mixed cryoglobulinemia that represents HCV/anti-HCV immune complex associated with rheumatoid factor and complement\[[@B7]\]. Epidemiological studies in the United States (NHANES III) and Taiwan have recently demonstrated the relationship between HCV infection and CKD\[[@B8],[@B9]\].

HCV infection is a frequent consequence of CKD in stages 4-5. Blood transfusions and nosocomial transmission in dialysis units contribute to the much higher prevalence of HCV infection in CKD stage 5 than in the general population. Epidemiological studies documented that HCV infection is associated with a higher risk and shorter time to CKD despite the lower prevalence of many CKD risk factors (ERCHIVES Study)\[[@B10]\]. Another study\[[@B11]\] confirmed that HCV-positive patients exhibit 40% higher odds for renal insufficiency compared with HCV-negative patients after adjustment for age, race, gender, diabetes and hypertension. One retrospective study\[[@B12]\] did not confirm these findings, but the authors recognized the limitation of their study. A relevant longitudinal study including of 23820 adults aged 30-65 years old was performed in Taiwan. The study included 18541 anti-HCV serum-negative patients and 1095 anti-HCV serum-positive patients. The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer (REVEAL)-HCV study is a large prospective community based cohort study in Taiwan, and long term diseases provide an excellent opportunity to investigate the natural history of chronic hepatitis C and long-term diseases associated with this chronic infection\[[@B13]\]. Lee et al\[[@B3]\] documented an association of HCV status and any cause of death. Lai et al\[[@B14]\] assessed the risk of developing end-stage renal disease (ESRD) in relation to HCV serostatus, HCV RNA level and HCV genotypes.

The Lai et al\[[@B14]\] study documented that chronic HCV infection is an independent risk factor for the development of ESRD. Participants with low and high HCV RNA levels exhibited a 2.6- and a 4.3-fold increased risk of developing ESRD, respectively, compared with participants who were not chronically HCV infected. Patients with HCV genotype 1 exhibit a higher risk of developing ESRD (Figure [1](#F1){ref-type="fig"}).
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CLINICAL PROBLEMS OF HEPATITIS C IN RENAL TRANSPLANT PATIENTS
=============================================================

Survival of HCV-infected patients in ESRD is significantly lower in HCV-positive RNA-positive dialysis patients compared to HCV-positive RNA-positive kidney transplant recipients\[[@B15]-[@B17]\]. However, the persistence of HCV infection after renal transplantation is a true risk factor for graft and patient survival. The following complications primarily occur after renal transplantation in HCV-positive patients.

Liver disease
-------------

Immunosuppression facilitates HCV replication and accelerates liver disease to result in chronic hepatitis, fibrosing cholestatic hepatitis and rapidly progressive liver failure\[[@B18],[@B19]\]. Therefore, preemptive treatment of HCV infection during dialysis is recommended.

Renal disease
-------------

HCV with associated cryoglobulinemia frequently causes MPGN even after renal transplantation\[[@B20],[@B21]\]. Similarly, HCV may cause membranous nephropathy in renal transplant patients\[[@B20],[@B22]\], and it may occur as a recurrent or de novo disease. A higher frequency of acute rejection was found in HCV-positive patients, but this association is controversial\[[@B23],[@B24]\]. Acute, often humoral, rejection is frequent in the patients receiving interferon (IFN) therapy\[[@B25]\]. Treatment of patients prior to transplantation is necessary, especially when IFN therapy is used. An increased risk of transplant glomerulopathy, the glomerular phenotype of chronic rejection, is associated with HCV infection\[[@B26],[@B27]\]. An increased risk of new onset diabetes mellitus is associated with HCV infection\[[@B28],[@B29]\]. An increase in post-transplant lympho-proliferative disorders was described in HCV patients transplanted with different organs\[[@B30]\].

These findings clearly document the need to manage HCV. The need for treatment during the dialysis period prior to transplantation is also clear. The standard therapy until recently consisted of IFN ± ribavirin administration, but the results were poor with this treatment. IFN was toxic, expensive and exhibited limited efficacy in the pre-transplant period. IFN treatment in the post-transplant period was also dangerous because it caused acute humoral rejections. HCV treatment may be divided in two periods: (1) IFN-based therapies; and (2) Direct acting antiviral (DAA) therapies.

IFN BASED THERAPIES
===================

The first drug used for the treatment of HCV-positive patients with ESRD or transplantation was the recombinant alpha interferon (IFNα) eventually in combination with ribavirin, but the results in terms of sustained viral response (SVR) were poor.

Recombinant IFNα was first used as a monotherapy for chronic hepatitis C, but the drug only produced a modest SVR, several side effects were reported, and treatment was expensive and generated severe acute rejection when used after transplantation\[[@B25],[@B31]-[@B35]\]. Fabrizi et al\[[@B36]\] performed a meta-analysis and concluded that the efficacy and safety of IFN-based therapies in renal transplant recipients were not satisfactory. The combination of IFNα with ribavirin increased the response rate, but induced the hemolysis as a new dose-dependent side effect\[[@B37]\]. This treatment was the standard of care until 1998. The introduction of pegylated IFNα increased the response rate by an additional 10%\[[@B38]\] and this treatment remained the standard of care until 2011.

The use of antiviral therapy was recommended for HCV patients in renal transplant candidates prior to transplantation because it was safer, effective and sustainable\[[@B1]\]. Several studies\[[@B39]-[@B44]\] confirmed these effects, including the Fabrizi et al\[[@B45]\] meta-analysis. One large randomized controlled trial recently demonstrated the greater efficacy and safety of combination antiviral therapy (pegylated IFN plus low-dose ribavirin, 200 mg daily) versus monotherapy (pegylated IFN alone) for HCV in a hemodialysis population\[[@B46]\]. The rates of sustained viral response were approximately 70%, and most dialysis patients tolerated the dual therapy well with appropriate patient monitoring.

DAA-BASED THERAPIES
===================

Accumulating evidence and knowledge of the mechanism of action of HCV and the viral proteins involved in its replication during the 2000s allowed for the development of specific drugs for direct antiviral treatment (Figure [2](#F2){ref-type="fig"}). To date the DAAs may be divided in four classes according the mechanism of action (Table [1](#T1){ref-type="table"})

###### 

The four classes of direct acting antivirals agents

  **The four classes of DAAs**                           **Mechanism of action**                                                                                                **Drugs (targeted genotypes in brackets)**
  ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  NS3/4A PIs (PIs)                                       Block a viral enzyme (protease) that enables the HCV to survive and replicate in host cells                            Glecaprevir (1-6) Paritaprevir (1, 4) Voxilaprevir (1-6) Grazoprevir (1, 3, 4)
  Nucleoside and nucleotide NS5B polymerase inhibitors   Target the HCV to stop it from making copies of itself in the liver. So doing block the virus from multiplying         Sofosbuvir (1-4)
  NS5A inhibitors                                        Block a virus protein, NS5A, that HCV needs to reproduce and for various stages of infection                           Ombitasvir (1, 4) Pibrentasvir (1-6) Daclatasvir (3) Elbasvir (1, 4) Ledipasvir (1) Ombitasvir (1) Velpatasvir (1-6)
  Non-nucleoside NS5B polymerase inhibitors              Stop HCV from reproducing by inserting themselves into the virus so that other pieces of the HCV cannot attach to it   Dasabuvir (1)

PIs: Protease inhibitors; HCV: Hepatitis C virus.
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The first stage of this therapeutic revolution was the therapeutic introduction of protease inhibitors (PIs). The first generation of DAAs was represented by boceprevir and telaprevir, which inhibited NS3/4A protease activity. These drugs are inhibitors and substrates of the cytochrome (CYP) 3A4 isoenzyme in the liver and the intestinal P-glycoprotein (Pgp) transporter. However, these drugs may develop viral resistance. Therefore, these DAAs must be combined with pegylated IFN and ribavirin. No dose adjustment is necessary for patients with hepatic or renal impairment\[[@B47]-[@B50]\].

New drugs target the 3 non-structural proteins of the NS3 serine protease. These serine PIs include simeprevir, paritaprevir and asunaprevir. Simeprevir is an inhibitor of gut cytochrome 3A4 and organic anion-transporting peptide 1B1/3 (OATP1B1/3), and treatment may produce indirect hyperbilirubinemia. Paritaprevir acts on the same cytochromes as simeprevir. These agents are better tolerated than boceprevir and telaprevir, but the antiviral activity is primarily limited to the HCV genotype I. These drugs remain subject to viral resistance and are used in combination with other antiviral drugs. No dose adjustments are necessary in patients with renal impairment\[[@B51]\].

Another group of DAAs are inhibitors of NS5A, such as daclatasvir, ledispasvir and ombitasvir. These drugs inhibit the NS5A protein that controls phosphorilation/hyperphosphorilation and plays a vital role in HCV viral replication. These drugs also exhibit a low barrier of resistance and must be used in combination in combination with others antiviral\[[@B51]\]. No dose adjustments are necessary in patients with CKD.

The newest DAAs include the NS5B inhibitors. These agents are divided into two classes: Nucleoside and non-nucleoside inhibitors. Non-nucleoside inhibitors are less potent, produce viral resistance and are less frequently used\[[@B51]\]. The most important nucleoside NS5B inhibitor is sofosbuvir, which was recently approved for use in combination with other DAAs. Sofosbuvir targets HCV RNA synthesis at the catalytic site of the NS5B enzyme. Incorporation into the new RNA by the polymerase leads to premature chain termination. Numerous IFN-free regimens are in phase 2 and phase 3 clinical trials and these combination regimens attained SVR in 90%-95% of patients\[[@B52]-[@B54]\]. Two publications summarize these drugs\[[@B55],[@B56]\]. Figure [3](#F3){ref-type="fig"} illustrates SVR improvement over time with different therapies for HCV genotype 1. These data refer to the general population.
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EFFECTS OF DAAs IN PATIENTS WITH ESRD AND ON WAITING LISTS FOR RENAL TRANSPLANTATION
====================================================================================

The prevalence of HCV infection in dialysis patients and patients on waiting lists for renal transplantation is high, between 6% and 40% and varies geographically\[[@B57],[@B58]\]. In the Dialysis Outcomes Practice Patterns Study (DOPPS) the seroprevalence of HCV infection varies from 20% to 50% according the length on dialysis\[[@B59]\].

Patients with kidney disease are difficult to treat because they present with a high rate of co-morbid conditions, such as hypertension, diabetes mellitus and cardiovascular disease. Co-morbidities facilitate several adverse effects. Few data exist on the pharmacokinetics of DAAs in patients with reduced glomerular filtration rate (GFR). Drug-drug interactions between DAAs and drugs used for lipid-lowering and cardiovascular disease were reported\[[@B60]\]. Table [2](#T2){ref-type="table"} lists the currently available approved DAA-based regimens for the treatment of HCV in patients with renal failure based on HCV genotype\[[@B61]\].

###### 

Available, approved direct acting antiviral-based regimens for treating hepatitis C virus in treatment-naive patients

  **Genotype 1a**                                                                                                **Genotype 4**
  -------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir Sofosbuvir+ simeprevir ± ribavirin   Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin Sofosbuvir + ribavirin + pegIFN Sofosbuvir + simeprevir + ribavirin
  **Genotype 1b**                                                                                                **Genotype 5**
  Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir Sofosbuvir + simeprevir              Sofosbuvir + ribavirin PegIFN + ribavirin
  **Genotype 2**                                                                                                 **Genotype 6**
  Sofosbuvir + ribavirin                                                                                         Ledipasvir + sofosbuvir Sofosbuvir + ribavirin + pegIFN
  **Genotype 3**                                                                                                 **Pangenotype**
  Sofosbuvir + ribavirin Sofosbuvir + ribavirin + pegIFN                                                         Glecaprevir + pibrentasvir Sofosbuvir + velatapasvir

pegIFN: Pegylated interferon.

The first-wave DAAs (*e.g*., boceprevir and telaprevir) exhibited poor efficacy and few patients were treated with these agents. SVR was less than 70% and combination with IFN and ribavirin was mandatory because of viral resistance. Pockros et al\[[@B62]\] demonstrated that the combination of ombitasvir, paritaprevir and ritonavir produced SVR in 90% of patients with genotype 1 and stage 4/5 CKD. The regimen was well tolerated, and only the addition of ribavirin produced anemia (Study RUBY I NCT02207088). A more recent study\[[@B63]\] treated 104 patients with CKD and HCV genotypes 1, 2, 3, 4, 5 or 6 with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 3 mo. SVR was obtained in 98% of patients with few adverse events primarily consisting of pruritus, fatigue and nausea (NCT 02651194).

The C-SURFER study (NCT02092350) is a phase 3 study of the administration of NS3/4A protease inhibitor granzoprevir (100 mg) and the NS5A inhibitor elbasvir (50 mg) to 111 patients for 12 wk. The control group received placebo. SVR was obtained in 94.3% of patients, and only 4% of patients reported adverse events, which consisted of headache, nausea and fatigue\[[@B64],[@B65]\]. The recent approval of the first pangenotypic NS5B inhibitor, sofosbuvir, revolutionized the treatment of HCV infection.

Sofosbuvir is a uridine nucleotide analog that inhibits hepatitis C RNA-dependent RNA polymerase and it is effective in all hepatitis C genotypes. Phase II and phase III studies reported that genotype I patients who received sofosbuvir in combination with other DAAs achieved a sustained virological response rate greater than 90%. Different drug associations with sofosbuvir are suggested based on the HCV genotype\[[@B66]\]. Several studies demonstrated the efficacy and safety of these associations\[[@B67],[@B68]\]. Some of these associations are principally useful in particular conditions. For example the association of sofosbuvir and velapatasvir revealed to be efficient in the case of HCV genotype 1, 2 and 3\[[@B69]\] and as rescue therapy in patients who developed viral resistance\[[@B53]\]. Many of these studies were performed in the context of the HCV-TARGET study.

HCV-TARGET is an observational longitudinal survey of patients affected by HCV different genotypes with different levels of renal function. The study is performed at academic and community medical centers in North America and Europe. The study evaluates the efficacy and safety of antiviral regimens, including sofosbuvir, in 1893 patients (NCT01474811).

Sofosbuvir use was restricted to patients with an eGFR \> 30 mL/min, and a few studies investigated the use of sofosbuvir in patients with ESRD\[[@B70]-[@B73]\]. Recently, the combination of sofosbuvir plus simeprevir was administered to 17 patients with ESRD. The SVR was 100% after 12 wk treatment. Few patients reported minor or mild adverse events\[[@B70]\].

Rostaing et al\[[@B74]\] recently reviewed the treatment of HCV infection in kidney transplant candidates with poor renal function or on dialysis. Saxena et al\[[@B75]\] reported the efficacy of sofosbuvir in association with ribavirin in 73 patients with an eGFR \< 45 mL/min, and SVR was achieved in 83% of patients. However, these patients exhibited higher rates of anemia and deterioration of renal function regardless of the use of ribavirin. Because of this fact and because of pharmacokinetic studies, sofosbuvir should be administered with extreme caution to patients with reduced GFR. Indeed, the use of sofosbuvir in patients with renal impairment causes an increase in serum levels of sofosbuvir and an increase of the AUC of 171%. Desnoyer et al\[[@B76]\] performed a pharmacokinetic study in hemodialysis patients receiving two different doses of sofosbuvir and demonstrated that sofosbuvir did not accumulate in either regimen. Beinhardt et al\[[@B77]\] treated 25 patients (10 on dialysis and 15 had received renal or combined liver-renal transplantation with sofosbuvir in association with other DAAs. SVR was obtained in 96% of patients after 12 and 24 wk of treatment, but the treatment response was slower in hemodialysis patients\[[@B77]\]. Alternative treatments for patients with ESRD were reported recently from Japan, where the combined use of daclatasvir plus asuneprevir in genotype I dialysis patients achieved a very high SVR rate\[[@B78]-[@B80]\].

EFFECTS OF DAAs ON KIDNEY TRANSPLANT PATIENTS WITH HCV INFECTION
================================================================

We highlighted that the treatment of HCV renal transplant patients in the IFNα era was dangerous, poorly effective and frequently produced acute humoral rejection. Several recent studies demonstrated that the HCV infection eradication was feasible in renal transplant patients using DDAs, with few treatment-related side effects. However, these studies are recent, and the first guidelines for the use of DDAs in renal transplant patients were published at the end of 2017.

Colombo et al\[[@B81]\] performed a recent phase 2, open-label clinical trial to evaluate the safety and efficacy of the combination of ledipasvir and sofosbuvir in 5 European centers in 114 renal transplant patients infected with chronic genotype 1 or 4 HCV (NCT 02251717). The authors obtained SVR in 100% of patients after 12 wk of treatment. The eGFR remained stable, and adverse events were common (64%) and included headache, asthenia and fatigue. In one center the association of amiodarone and sofosbuvir probably caused a bradyarrhithmia and the patient interrupted the treatment\[[@B82]\]. The authors concluded that treatment with ledipasvir-sofosbuvir for 12 wk was well tolerated and achieved SVR in 12 wk with an acceptable safety profile. Sawinski et al\[[@B83]\] treated 20 renal transplant patients with HCV infection with a sofosbuvir-based therapy. SVR was obtained in all patients at 12 wk. Renal function remained stable, and no rejection occurred. However, 45% of patients required a dose reduction of the calcineurin inhibitor while receiving treatment. Saxena et al\[[@B84]\] reported the efficacy of DDAs therapy in 443 patients who received kidney (60) or liver transplant (347) or combined liver-kidney transplantation (36). The study was performed in the context of the vast HCV-TARGET study. Most patients had HCV genotype I. Patients were treated with sofosbuvir/ledipasvir ± ribavirin (85%), sofosbuvir plus daclatasvir ± ribavirin (9%) and ombitasvir/paritaprevir plus dasabuvir ± ribavirin (6%). SVR was achieved in 95.9% of patients after 12 wk of treatment. Six episodes of acute rejection occurred during HCV treatment. The authors concluded that different combinations of DAAs were effective and safe in kidney and/or liver transplant patients. Ribavirin did not influence SVR, and graft rejections were rare. Kamar et al\[[@B85]\] demonstrated the efficacy and safety of sofosbuvir-based antiviral therapy for HCV infection after renal transplantation in 25 patients. HCV RNA was not detectable in any patient 12 wk after completing DAA therapy. Treatment was well tolerated without graft rejections or reductions in renal function. Kamar did not observe any drug interaction with calcineurin inhibitors. These data differ from the findings of most studies. Hussein et al\[[@B86]\] reported the successful treatment of HCV genotype 4 in 3 renal transplant patients using the combination of sofosbuvir and ribavirin. Fernández et al\[[@B87]\] recently published data of the HepaC, which is a Spanish registry of 103 patients treated with DAAs after kidney transplantation. Most patients received a combination of sofosbuvir/ledipasvir or sofosbuvir/daclatasvir. The SVR at 12 wk was 98%. Three episodes of acute humoral rejection occurred, but there were no statistically significant differences in serum creatinine, eGFR or proteinuria before and after treatment. Most patients required immunosuppression dose adjustment, and 36% of patients, mostly cirrhotic, experienced renal dysfunction during antiviral treatment. The authors concluded that a close follow-up is required during treatment because of adjustments in immunosuppression therapy.

The phase 3, open-label, single-arm MAGELLAN-2 study evaluated a 12-wk course of the combination of the pangenotypic NS3/4A inhibitor glecaprevir and the pangenotypic NS5A inhibitor pibrentasvir in liver or renal transplant patients with chronic HCV genotype 1-6. Previous studies demonstrated that all these drugs exhibited a high barrier to resistance, sufficient potency against common NS3 and NS5A polymorphisms and synergistic antiviral activity. The study involved 80 liver transplant patients and 20 kidney transplant patients. The study demonstrated that the treatment with this combination for 12 weeks achieved a 99% SVR in patients with HCV genotypes 1-6. The treatment was well tolerated with few adverse events and confirmed the results obtained by Gane et al\[[@B63]\] in patients with ESRD. This new association represents an important alternative in treatment HCV patients after transplantation\[[@B88]\].

The American Association for the Study of Liver Diseases (AASLD) published the following HCV guidelines for kidney transplant patients in 2017\[[@B89]\] (Table [3](#T3){ref-type="table"}): (1) The recommended drug association for the treatment of naïve and experienced kidney transplant patients with a genotype 1 or 4 infection: Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) for 12 wk. An alternative is a daily fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 wk; and (2) The recommended association for the treatment of naïve and experienced kidney transplant patients with HCV genotypes 2, 3, 5 and 6: Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) for 12 wk. An alternative is daily daclatasvir (60 mg) plus sofosbuvir (400 mg) and a low initial dose of ribavirin for 12 wk.

###### 

Recommended regimens for kidney transplant patients

  **Recommended**                                                                                                                                                                                         **Duration**   **Rating**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------------
  Recommended regimens listed by evidence level and alphabetically for treatment-naive and experienced kidney transplant patients with genotype 1 or 4 infection, with or without compensated cirrhosis                  
  Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)                                                                                                                              12 wk          I, A[1](#T3FN1){ref-type="table-fn"}
  IIa, C[2](#T3FN2){ref-type="table-fn"}                                                                                                                                                                                 
  Daily fixed dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)                                                                                                                                  12 wk          I, A
  Recommended and alternative regimens for treatment-naïve and experienced kidney transplant patients with genotype 2, 3, 4, 5 or 6 infection, with or without compensated cirrhosis                                     
  Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)                                                                                                                              12 wk          I, A[3](#T3FN3){ref-type="table-fn"}
  IIa, C[4](#T3FN4){ref-type="table-fn"}                                                                                                                                                                                 
  Alternative                                                                                                                                                                                                            
  Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) plus low initial dose of ribavirin (600 mg; increased as tolerated)                                                                                  12 wk          II, A

Patients without cirrhosis;

Patients with compensated cirrhosis;

Genotypes 2, 3 and 6;

Genotype 5.

Pharmacokinetic warning for transplant patients
-----------------------------------------------

The most important factor to be considered in the treatment of HCV-infected renal transplant patients with DAAs is the possible interactions between DAAs and immunosuppressants. Kwo et al\[[@B90]\] recently reviewed this issue and found the following results: Sofosbuvir may be administered to transplant patients without any expected interaction with calcineurin inhibitors. A recent report\[[@B91]\] demonstrated no interaction with mycophenolate mofetil, prednisone or azathioprine. The combination of sofosbuvir and ledipasvir did not reveal any significant interaction with calcineurine inhibitors. No data on possible interactions with sirolimus or everolimus are available. The NS34A protease inhibitor simeprevir did not interact with tacrolimus (TAC), but recent pharmacokinetic studies demonstrated a 5.81-fold increase in the simeprevir AUC levels when administered with cyclosporine (CsA). Therefore, simeprevir should not be administered with CsA. A pharmacokinetic analysis was performed in patients receiving the combination of paritaprevir, ombitasvir and dasabuvir with TAC\[[@B92]\]. There was a 57-fold increase in the TAC AUC, and modeling suggested 0.5 mg of TAC every 7 d with strict monitoring of the TAC levels. A 5.8-fold increase in the CsA AUC was similarly observed, and CsA should be reduced to 1/5. No interaction data are available for paritaprevir, ombitasvir and dasabuvir with sirolimus and everolimus, and the co administration is not recommended. The NS5A inhibitor daclatasvir does not affect the CsA or TAC levels and no dose adjustment is required. The combination of elbasvir and grazoprevir produced a 15-fold increase in the grazoprevir AUC when administered with CsA, and this association is not recommended\[[@B89]\]. The combination of glecaprevir and pibrentasvir with CsA produced a 5-fold increase in the glecaprevir AUC when high doses of CsA were used. This same drug combination with TAC produced a 1.45-fold increase in the TAC AUC, and careful monitoring of the TAC levels is required\[[@B89]\]. Fernández-Ruiz et al\[[@B93]\] recently examined eGFR and 24-h proteinuria in 49 renal transplant patients who received sofosbuvir and ledipasvir for 12 mo after treatment. The TAC levels were higher at 12 mo compared to the end of treatment, and the eGFR was significantly decreased. The authors suggested adjusting immunosuppressants when DAAs are administered. Drug monitoring should also be performed after the end of the HCV treatment as well as monitoring of the renal function.

TRANSPLANTING KIDNEYS FROM HCV POSITIVE DONORS INTO HCV POSITIVE RECIPIENTS
===========================================================================

In the pre DAAs era, because of organ shortage, several transplant centers transplanted kidneys from HCV positive donors into HCV positive recipients. The issue was controversial. One of the largest reports using such strategy is the study of Morales et al\[[@B94]\]. In this study 162 HCV positive recipients received a kidney from HCV positive donors and were compared with 306 HCV positive recipients who received kidney from HCV negative donors. The 5 and 10 year patients survival was similar as well as the 5 and 10 years graft survival. The outcomes of the liver disease were also similar in both groups and the Cox regression analysis could not identify the donor's HCV serology as a significant risk factor. These data strongly suggest the use of kidneys from HCV positive donors in HCV positive recipients. Accordingly, the Kidney Disease Improving Global Outcomes (Kdigo)\[[@B1]\] recommended that transplantation of kidneys from HCV RNA positive donors should be directed to the HCV positive recipients. In United States, currently patients with untreated hepatitis C, who accept organ from HCV positive donors, may have a shorter time on transplant waiting list, while in other continents as Europe the positions differ according the different national programs. As afore mentioned direct-acting antiviral has revolutionized the treatment of hepatitis C infection also with implications for the use of HCV vermeil donors. Two recent papers reported the safety of transplanting kidneys from HCV positive donors to HCV positive recipients using DAAs\[[@B95],[@B96]\]. The recommendation is to initiate early post-transplantation a pan-genotype therapy. A sustained SVR was near 100% and the DAA treatment after surgery was 125 d. Looking forward, the American Society of Transplantation (AST) held a consensus conference on the use of HCV viremic donors in solid organ transplantation\[[@B97]\].

The consensus conclusions established that: The term "HCV viremic donors" should be adopted; The provision of DAA to allow transplantation of HCV viremic donors into negative recipients is justified; The transplantation of organs from HCV viremic donors into HCV-negative recipients should be conducted only under monitored protocols and studies; There is a need for well-designed clinical trials of adequate power with conclusive findings to justify payer coverage of DAAs medications.

In this context the trial Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients (EXPANDER 1)\[[@B98]\] was started at the Johns Hopkins University. If the donor had genotype 1, the treatment included Grazoprevir and Elbasvir started immediately after transplantation and continued for 12 weeks. If the donor had genotype 1 with resistance variants, ribavirin was added. If the donor had genotype 2 or 3, sofosbuvir will be added. The data of this pilot study has been presented at the American Transplant Congress (ATC) 2017. Eight patients have been treated. After treatment no recipient had HCV-RNA detected and no graft failure was observed\[[@B99]\].

CONCLUSION
==========

There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens combining direct-acting antivirals (DAAs) from different families (NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors, NS5A replication complex inhibitors and NS3/4A PIs) have been developed. These regimens result in an increase in sustained virological response (SVR) rates to above 90% and reduce the duration of treatment to 12 wk or less. As of 2017 several regimens will be approved with additive potencies, without cross-resistance and with a good safety profile. Remaining issues will include increasing screening and access to care so that HCV may become the first chronic viral infection eradicated worldwide.

The efficacy and safety of these new DAAs are primarily important in the field of renal diseases of patients affected by ESRD and of patients in dialysis waiting for a renal transplant and in patients already transplanted, but with HCV infection. The problem of HCV infection was particularly relevant in uremic patients in the pre-DAAs era and HCV was difficult to be eradicated. The main studies in this field are cited in Table [4](#T4){ref-type="table"}. Table [5](#T5){ref-type="table"} and Table [6](#T6){ref-type="table"} shows the recommendations for treating HCV in patients with renal impairment given from the American Association for the study of liver disease (AASLD)\[[@B90]\] and the European Association for the Study of the Liver (EASL)\[[@B60]\]. The access to transplantation to dialysis patients was allowed, but complications after transplantation were frequent and treatment was not possible after transplantation.

###### 

Main literature studies with direct acting antiviral therapy in patients with chronic hepatitis C and renal dysfunction

  **Ref**.   **Title**                                                                                                                                                                                                                                           **Journal**                      **Year**
  ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ----------
  \[62\]     Efficacy of direct-acting antiviral combination for patients with HCV genotype 1 infection and severe renal impairment or end-stage renal disease                                                                                                   *Gastroenterology*               2016
  \[63\]     Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment                                                                                                                                                                       *N Engl J Med*                   2017
  \[64\]     Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study                                                *Lancet*                         2015
  \[65\]     Elbasvir plus grazoprevir in patients with HCV infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomized, double-blind, placebo-controlled trial   *Lancet Gastroenterol Hepatol*   2017
  \[70\]     Use of sofosbuvir-based direct-acting antiviral therapy for HCV infection in patients with severe renal insufficiency                                                                                                                               *Infect Dis*                     2015
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HCV: Hepatitis C virus.

###### 

American Association for the Study of Liver Diseases Recommendation for treating hepatitis C virus in patients with renal impairment

  **Recommended**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Rating**   **Genotype**       **Duration**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------------ --------------
  Recommendations for patients with CKD stage 1, 2 or 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  No dose adjustment is required when using (1) Daclatasvir (60 mg) (2) Daily fixed-dose combination of elbasvir (50 mg)/grazopevir (100 mg) (3) Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (4) Fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) (5) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) (6) Simeprevir (150 mg) (7) Fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) (8) Sofosbuvir (400 mg)   I, A                            
  Recommendations for patients with CKD stage 4 or 5 (eGFR \< 30 mL/min or ESRD                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                I, B         1a, 1b, 4          12 wk
  Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                           I, B         1, 2, 3, 4, 5, 6   8 to 16 wk

CKD: Chronic kidney disease; ESRD: End-stage renal disease.

###### 

European Association for the Study of the Liver Recommendations for treating hepatitis C virus in patients with reduced or absent renal function

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hemodialysis patients, particularly those who are suitable candidates for renal transplantation, should be considered for antiviral therapy (B1)
  Hemodialysis patients should receive an IFN-free, if possible ribavirin-free regimen, for 12 wk in patients without cirrhosis, for 24 wk in patients with cirrhosis (B1)
  Simeprevir, daclatasvir, and the combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir are cleared by hepatic metabolism and can be used in patients with severe renal disease (A1)
  Sofosbuvir should not be administered to patients with an eGFR \< 30 mL/min per 1.73 m^2^ or with end-stage renal disease until more data is available (B2)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DAAs are able to eradicate HCV in dialysis patients with a short course therapy obtaining a SVR close to 100%. Additionally, DAA-treatment is successful even after transplantation. Particular attention must be devolved to the interference between DAAs and calcineurin inhibitors. Either an increase of CsA or TAC AUC or an increase of DAA AUC is possible and monitoring is essential even after long time after transplantation
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